GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE343nnn/GSE343570/primaryOK200TranscriptomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE343570GEOGSEfalsePembrolizumab with or without vorinostat in first-line metastatic non-small cell lung cancer: a randomized phase 2 trialBulk RNA sequencing was performed on fresh-frozen tumor biopsies collected from patients with treatment-naïve metastatic non-small cell lung cancer (NSCLC) enrolled in a randomized phase II clinical trial comparing pembrolizumab monotherapy with pembrolizumab plus the histone deacetylase inhibitor vorinostat. Tumor biopsies were obtained before treatment and during cycle 1 (days 14–21) to characterize treatment-induced transcriptional changes associated with PD-1 blockade alone or in combination with HDAC inhibition.2026/09/22GSE343570GSM9957535GSM9957536GSM9957537GSM9957538GSM9957531GSM9957498GSM9957532GSM9957499GSM9957533GSM9957534GSM9957539GSM9957494GSM9957495GSM9957496GSM9957497GSM9957530GSM9957490GSM9957491GSM9957492GSM9957493GSM9957546GSM9957502GSM9957503GSM9957504GSM9957505GSM9957542GSM9957543GSM9957500GSM9957501GSM9957545GSM9957506GSM9957507GSM9957508GSM9957509GSM9957540GSM9957541GSM9957513GSM9957514GSM9957515GSM9957516GSM9957510GSM9957511GSM9957512GSM9957479GSM9957517GSM9957518GSM9957519GSM9957524GSM9957525GSM9957526GSM9957527GSM9957520GSM9957487GSM9957488GSM9957521GSM9957489GSM9957522GSM9957523GSM9957528GSM9957529GSM9957483GSM9957484GSM9957485GSM9957486GSM9957480GSM9957481GSM995748230173343570Homo sapiens